Probiotics for Vaginal Dysbiosis and Recurrent Bacterial Vaginosis: A Narrative Review of Strain-Specific Evidence

Bacterial vaginosis (BV) is a common manifestation of vaginal dysbiosis, and recurrence after antimicrobial therapy remains frequent. This narrative review examines the rationale for restoring vaginal lactobacilli and evaluates oral and intravaginal interventions using selected clinical trials, evidence syntheses, and practice guidance. In a phase 2b trial, intravaginal Lactobacillus crispatus CTV-05 following metronidazole reduced 12-week recurrence from 45% to 30%. Trials of oral Lacticaseibacillus rhamnosus GR-1 plus Limosilactobacillus reuteri RC-14 reported inconsistent short-term cure outcomes. Meta-analyses suggest a reduction in BV recurrence with some preparations, with uncertainty arising from differences in strains, formulations, timing, and outcome definitions. Small trials of vaginal prebiotic gels report improvements in microbiological measures, while evidence for durable benefit remains limited. Available data provide insufficient support for extrapolating BV findings to vulvovaginal candidiasis, human papillomavirus clearance, or shiitake-derived adjuncts. The clearest evidence concerns specific interventions tested after standard BV treatment. Future trials should measure symptomatic recurrence alongside strain persistence and assess whether protection persists after dosing ends.

Authors

Publication Details

Journal
Preprints.org
Published
2026-11-17
DOI
https://doi.org/10.20944/preprints202611.1660.v1
Primary Topic
Reproductive tract infections research
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Probiotics for Vaginal Dysbiosis and Recurrent Bacterial Vaginosis: A Narrative Review of Strain-Specific Evidence

Paria Jafari
1 links
Preprints.org
Reproductive tract infections research
preprint

Probiotics for Vaginal Dysbiosis and Recurrent Bacterial Vaginosis: A Narrative Review of Strain-Specific Evidence

Paria Jafari
preprint en

Abstract

Bacterial vaginosis (BV) is a common manifestation of vaginal dysbiosis, and recurrence after antimicrobial therapy remains frequent. This narrative review examines the rationale for restoring vaginal lactobacilli and evaluates oral and intravaginal interventions using selected clinical trials, evidence syntheses, and practice guidance. In a phase 2b trial, intravaginal Lactobacillus crispatus CTV-05 following metronidazole reduced 12-week recurrence from 45% to 30%. Trials of oral Lacticaseibacillus rhamnosus GR-1 plus Limosilactobacillus reuteri RC-14 reported inconsistent short-term cure outcomes. Meta-analyses suggest a reduction in BV recurrence with some preparations, with uncertainty arising from differences in strains, formulations, timing, and outcome definitions. Small trials of vaginal prebiotic gels report improvements in microbiological measures, while evidence for durable benefit remains limited. Available data provide insufficient support for extrapolating BV findings to vulvovaginal candidiasis, human papillomavirus clearance, or shiitake-derived adjuncts. The clearest evidence concerns specific interventions tested after standard BV treatment. Future trials should measure symptomatic recurrence alongside strain persistence and assess whether protection persists after dosing ends.

Preprints.org
Good health and well-being
Reproductive tract infections research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon